Will Gene Therapy Make Specialty Pharmacy Obsolete?
Another $2.8 million gene therapy was approved this month. So, we need to ask….. Are we looking forward to the day when specialty pharmacies as
August 25, 2022
Another $2.8 million gene therapy was approved this month. So, we need to ask….. Are we looking forward to the day when specialty pharmacies as
Last week, the FDA approved yet another one-and-done gene therapy, Zynteglo (betibeglogene-autotemcel) from Bluebird Bio, for the treatment of adult and pediatric patients with beta-thalassemia
Earlier this year CVS published a sponsored article in Fierce Healthcare that raised a red flag around the concept of a specialty pharmacy carve-out. Before we
A recent DoJ press release (below) is a stark reminder for specialty pharmacies that they need to ensure strict compliance with federal and state laws
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
The FDA just approved another biosimilar! That’s always big news that often starts a panic in the healthcare industry…. said no one ever. However, this new
CVS recently released its a Drug Trend Report for 2021. Caremark found that 35.9% of its clients saw negative specialty trend in 2021. In addition, 65.3% saw
Walgreens continues to morph into a diverse health services company. The headline of the article below isn’t the real news. Rather, the article below lists
Curiouser and curiouser…….Over the past three years the three largest PBMs each formed a GPO to, in their words, “capitalize on scale to get better
We’ve been watching the slow but steady growth of value based contracting (VBCs) for some years now. Conceptually VBCs make a lot of sense. Payors
